SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche group (SIX: RO, ROG; OTCQX: RHHBY), today announced new analyses from the three OCREVUS™ (ocrelizumab) Phase III studies in relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) will be presented during the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), from September 14-17 in London, England. OCREVUS increased disease control in pati
The laser is used in small-incision lenticule extraction to reshape the cornea and reduce or eliminate nearsightedness. FDA Approvals
Response after 12 weeks of ranibizumab therapy can predict long-term outcomes in diabetic macular edema, a post hoc analysis suggests. Medscape Medical News
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “India CR39 Eyeglasses Market Forecasts to 2021 – High Prevalence of Impaired Vision and Increasing Awareness to Fuel Growth” report to their offering. The research report …
COPENHAGEN — Capsular tension rings used during cataract surgery improved refractive outcomes in high myopes, according to a study presented here.The retrospective case review compared refractive outcomes in highly myopic patients undergoing routine cataract surgery with and without capsular tension rings in place during the procedure.
COPENHAGEN — Registry data from the recently concluded LUMINOUS study, a real-life observational study on the long-term safety, effectiveness, treatment patterns and quality-of-life outcomes related to the use of Lucentis, were shown and discussed by Paolo Lanzetta, MD, at the Euretina meeting.The study enrolled more than 30,000 patients in 40 countries from different continents and gathered information on retinal vascular diseases, including age-related macular degeneration, diabetic macular edema, retinal vein occlusion and myopic choroidal neovascularization.